Gerald Wolfgang Prager

19PUBLICATIONS
93CO-AUTHORS
Molecular targetsCancer cell biologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

|Oct 08, 2025
Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Teresa Macarulla, Cindy Neuzillet, Gerald W Prager

|Sep 09, 2025
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.

Karin Potthoff, Jens Uhlig, Lutz Jacobasch

|Aug 29, 2025
Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort.

Hannah C Puhr, Luzia Berchtold, Linda Zingerle

|Jul 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.

Federica Lo Prinzi, Francesca Salani, Silvia Camera

|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.

Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi

Pageof 4

Frequent Collaborators

4 joint publications

Anna S Berghoff

4 joint publications

Hannah C Puhr

4 joint publications

Matthias Preusser

3 joint publications

Julien Taieb